Anti-HCV Activity from Semi-purified Methanolic Root Extracts ofValeriana wallichii
- 12 January 2017
- journal article
- research article
- Published by Wiley in Phytotherapy Research
- Vol. 31 (3) , 433-440
Abstract
Hepatitis C virus (HCV) is a serious global health problem affecting approximately 130–150 million individuals. Presently available direct-acting anti-HCV drugs have higher barriers to resistance and also improved success rate; however, cost concerns limit their utilization, especially in developing countries like India. Therefore, development of additional agents to combat HCV infection is needed. In the present study, we have evaluated anti-HCV potential of water, chloroform, and methanol extracts from roots of Valeriana wallichii, a traditional Indian medicinal plant. Huh-7.5 cells infected with J6/JFH chimeric HCV strain were treated with water, chloroform, and methanol extracts at different concentrations. Semi-quantitative reverse transcription polymerase chain reaction result demonstrated that methanolic extract showed reduction in HCV replication. The methanolic extract was fractionated by thin layer chromatography, and the purified fractions (F1, F2, F3, and F4) were checked for anti-HCV activity. Significant viral inhibition was noted only in F4 fraction. Further, intrinsic fluorescence assay of purified HCV RNA-dependent RNA polymerase NS5B in the presence of F4 resulted in sharp quenching of intrinsic fluorescence with increasing amount of plant extract. Our results indicated that methanolic extract of V. wallichii and its fraction (F4) inhibited HCV by binding with HCV NS5B protein. The findings would be further investigated to identify the active principle/lead molecule towards development of complementary and alternative therapeutics against HCV. Copyright © 2017 John Wiley & Sons, Ltd.Keywords
This publication has 43 references indexed in Scilit:
- In vitro antiviral activity of plant extracts from Asteraceae medicinal plantsVirology Journal, 2013
- Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanismJournal of Hepatology, 2011
- Pegylated interferon and ribavirin treatment for hepatitis C virus infectionTherapeutic Advances in Chronic Disease, 2010
- Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5BViruses, 2010
- Multiple Effects of Silymarin on the Hepatitis C Virus LifecycleHepatology, 2010
- Identification of hepatoprotective flavonolignans from silymarinProceedings of the National Academy of Sciences of the United States of America, 2010
- Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: A meta-analysisJournal of Hepatology, 2009
- Treatment failure in hepatitis C: Mechanisms of non-responseJournal of Hepatology, 2008
- Treating viral hepatitis C: efficacy, side effects, and complicationsGut, 2006
- The Role of Plant-Derived Drugs and Herbal Medicines in HealthcareDrugs, 1997